Therapeutic Expertise

GLP-1 RA

Provide full lifecycle solutions for GLP-1 RA clinical research from preclinical to Phase IV.

GLP-1 RA Drug Clinical Development

Tigermed's GLP-1 drug R&D solution offers integrated, full-life-cycle services from preclinical to Phase IV clinical development. Our capabilities cover non-clinical research (animal efficacy, toxicology, DMPK), regulatory submission, clinical development strategy, medical writing, medical monitoring, operations, biostatistics, clinical pharmacology and quantitative pharmacology, drug safety surveillance, comparator drug procurement, central laboratory, and more. In addition, through digital technologies and innovative models such as DCT (Decentralized Clinical Trials), remote monitoring combined with on-site monitoring, we can effectively enhance the quality and efficiency of clinical development while reducing R&D costs.

Over the years, our team has collaborated with over 200 research centers across China, helping GLP-1 drugs operate efficiently and rapidly, contributing to the successful approval of innovative drugs for a wide range of indications, including diabetes, obesity, cardiovascular diseases, non-alcoholic steatohepatitis (NASH), and chronic kidney disease, thereby benefiting patients.

Through Tigermed's innovative drug integrated R&D service platform, we look forward to promoting the launch of more GLP-1 drugs, accelerating the development of breakthrough therapies, and driving transformation in future disease treatment and health management.

200+

Collaborating sites with GLP-1 Receptor Agonist (RA) drug clinical trial experience

An in-house therapeutic area team with extensive knowledge and experience in GLP-1 biology, pharmacology, and clinical research, which allows us to provide valuable insights and tailored support throughout all stages of GLP-1 research.

A leading CRO partner in diabetes clinical research with hands-on experience and KOL resources, supported by a network of industry experts and academic organization.

Leveraging innovative technologies like hybrid model of remote + onsite monitoring, as well as comprehensive approaches to effectively manage complex GLP-1 clinical trials.

Therapeutic Expertise

Diabetes, Obesity, Cardiovascular Diseases, Non-alcoholic Fatty Liver Disease (NAFLD), Chronic Kidney Disease, etc.

Let's Connect for a Conversation